<DOC>
	<DOCNO>NCT01496339</DOCNO>
	<brief_summary>The purpose study investigate whether treatment human menstrual blood-derived mesenchymal stem cell would apply diabetes patient safe effective .</brief_summary>
	<brief_title>Human Menstrual Blood-derived Mesenchymal Stem Cells Transplantation Treating Type 1 Diabetic Patients</brief_title>
	<detailed_description>Diabetes mellitus chronic metabolic diease cause absent rejection insulin pancreatic b cells.The traditional treatment strategy diabetes daily injection insulin transplantation islet cadaver . However , daily injuection inconvenient shortage organ life long immunosuppression . Therefore , therapy offer limited number patient . MSC-based therapeutic intervention become emerge strategy replacement injure tissue . MSCs also note possess immunomodulatory effect vivo . Thus , potential clinical use cell-based therapy focus observation .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>male female patient age 18 75. agreement receive write informed consent . voluntary submission procedure study protocol . clinical diagnosis classify type 1 diabetes ( T1DM ) . T1DM duration ≥ 1 ≤ 20 year time enrollment . renal dysfunction , eye disease organ disease . cardiovascular disease , exist congestive cardiac failure physical exam and/or acute coronary syndrome past 6 month . pregnancy mental disorder hepatitis C , HIV , RPR , active tuberculosis blood disease malignancy severe disease could potentially influence infusion result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>